The business in India, comprising a network of approximately 115 directly clinics and 460 employees, generated revenues of roughly 12 million euros in 2025 and had a dilutive impact on the Group’s EBITDA. The transaction is the result of the in-depth strategic review of Amplifon’s business segments carried out as part of the ‘Fit4Growth’ performance improvement program. The divesture will make a positive contribution to the Group’s adjusted EBITDA margin, and no material non-recurring charges are expected.